T1	Concept 37 46	monocytes
T2	Concept 51 62	macrophages
T3	Concept 75 100	pro-inflammatory cytokine
T4	Concept 108 149	murine hepatitis virus strain-3 infection
R1	causes Arg1:T2 Arg2:T3	
R2	causes Arg1:T1 Arg2:T3	
T5	Concept 163 173	SARS-CoV-2
R4	in-context Arg1:T3 Arg2:T4	
T8	Concept 210 219	monocytes
T9	Concept 224 235	macrophages
T7	Concept 188 204	cytokine release
R3	causes Arg1:T5 Arg2:T7	
R6	has-part Arg1:T8 Arg2:T7	
R7	has-part Arg1:T9 Arg2:T7	
T11	Action 197 204	release
T10	Concept 239 256	COVID-19 patients
R8	subject Arg1:T11 Arg2:T8	
R9	subject Arg1:T11 Arg2:T9	
R5	in-place Arg1:T5 Arg2:T10	
T6	Concept 354 369	high viral load
T12	Concept 373 383	SARS-CoV-2
R10	has-property Arg1:T6 Arg2:T12	
T13	Concept 384 418	at early stage after symptom onset
R11	in-time Arg1:T12 Arg2:T13	
T14	Action 420 444	suggested RT-LAMP assays
T15	Concept 469 484	screening tests
R12	target Arg1:T14 Arg2:T15	
T16	Concept 420 444	suggested RT-LAMP assays
R13	subject Arg1:T16 Arg2:T15	
T17	Concept 528 543	CCoV strain A76
T18	Concept 555 580	recombinant S 103 protein
R14	has-property Arg1:T17 Arg2:T18	
T19	Concept 584 649	product of recombination between serotype I and II CCoV sequences
R15	has-property Arg1:T17 Arg2:T19	
T20	Concept 650 660	SARS-CoV-2
T21	Concept 668 707	isordered segment from 168-289 residues
R16	has-property Arg1:T20 Arg2:T21	
T22	Concept 714 724	Human SARS
T23	Concept 747 792	an unstructured segment from 145-289 residues
R17	has-property Arg1:T22 Arg2:T23	
T24	Concept 798 817	potential evolution
T25	Action 844 854	appearance
T26	Concept 858 882	mild subtype of COVID-19
